. 2012 Mar 9;8:105–130. doi: 10.2147/TCRM.S29830

Table V.

Direct comparison of adverse events between the trial intervention (response-guided therapy duration telaprevir) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin)

Trial	Intervention		Control		Relative risk (95% CI)

	N	Pooled (95% CI)	N	Pooled (95% CI)
Anemia
Naïve patients
Jacobson et al8	135/363	38% (35%–42%)	70/361	19% (17%–22%)	1.96 (1.64–2.33)
	141/364	38% (35%–42%)	70/361	19% (17%–22%)	1.96 (1.64–2.33)
Neutropenia
Naïve patients
Jacobson et al8	51/363	16% (13%–19%)	69/361	19% (16%–22%)	0.81 (0.65–1.02)
	62/364	16% (13%–19%)	69/361	19% (16%–22%)	0.81 (0.65–1.02)
Rash
Naïve patients
Jacobson et al8	133/363	36% (33%–40%)	88/361	24% (21%–28%)	1.48 (1.26–1.74)
	129/364	36% (33%–40%)	88/361	24% (21%–28%)	1.48 (1.26–1.74)
Pruritus
Naïve patients
Jacobson et al8	181/363	48% (43%–52%)	131/361	36% (33%–40%)	1.31 (1.16–1.48)
	165/364	48% (43%–52%)	131/361	36% (33%–40%)	1.31 (1.16–1.48)

Abbreviation: CI, confidence interval.